Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies.

Xu, Gui-Qing; Gong, Xiao-Qing; Zhu, Ying-Ying; Yao, Xiao-Jun; Peng, Li-Zeng; Sun, Ge; Yang, Jian-Xue; Mao, Long-Fei

Xu, Gui-Qing; Gong, Xiao-Qing; Zhu, Ying-Ying; Yao, Xiao-Jun; Peng, Li-Zeng; Sun, Ge; Yang, Jian-Xue; Mao, Long-Fei.

Afiliação

Xu GQ; Henan Engineering Research Center of Chiral Hydroxyl Pharmaceutical, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Gong XQ; College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Zhu YY; Henan Engineering Research Center of Chiral Hydroxyl Pharmaceutical, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Yao XJ; College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Peng LZ; Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing Ministry of Agriculture, Institute of Agro-Food Science and Technology Shandong Academy of Agricultural Sciences, Jinan, China.
Sun G; The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Yang JX; Department of Neurology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Mao LF; School of Nursing, Henan University of Science and Technology, Luoyang, China.

Front Pharmacol ; 13: 854965, 2022.

Article em En | MEDLINE | ID: mdl-35677437

Palavras-chave

1,2,3-triazole; ADME analysis; DTI; cell assay; docking; erlotinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google